Cours Iovance Biotherapeutics Inc Nasdaq
Actions
US53619R1023
Recherche biotechnologique et médicale
CA 2024 * | 161 M 147 M | CA 2025 * | 413 M 376 M | Capitalisation | 3,25 Md 2,96 Md |
---|---|---|---|---|---|
Résultat net 2024 * | -352 M -320 M | Résultat net 2025 * | -245 M -223 M | VE / CA 2024 * | 19,3 x |
Trésorerie nette 2024 * | 133 M 121 M | Trésorerie nette 2025 * | 251 M 228 M | VE / CA 2025 * | 7,27 x |
PER 2024 * |
-8,97
x | PER 2025 * |
-16,1
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 92,7% |
Dernier transcript sur Iovance Biotherapeutics Inc
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30/09/16 |
Director of Finance/CFO | 51 | 14/12/20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20/07/11 |
Director/Board Member | 56 | 07/06/16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15/03/18 |
Varia. 1 janv. | Capi. | |
---|---|---|
-20,55% | 10,82 Md | |
-32,75% | 2,11 Md | |
-14,15% | 2,08 Md | |
-26,06% | 1,48 Md | |
+19,85% | 1,02 Md | |
-2,62% | 733 M | |
-31,67% | 391 M | |
-43,88% | 383 M | |
+29,03% | 332 M |